User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Search

Displaying 10 results.
    • Journal article
    Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study.
    Ajani, Jaffer El Hajbi, Farid Cunningham, David Alsina, Maria Thuss-Patience, Peter Scagliotti, Giorgio V Van den Eynde, Marc[UCL] Kim, Sung-Bae Kato, Ken Shen, Lin Li, Liyun Ding, Ningning Shi, Jingwen Barnes, Gisoo Van Cutsem, Eric (2024) ESMO open — Vol. 9, no.1, p. 102202 [1-9] (2024)
    • Speech
    120P Avelumab (AVE), cetuximab (CET) and irinotecan (IRI) for treatment refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Characterization of the circulating immune response in the AVETUXIRI phase II trial
    Benidovskaya, Elena[UCL] Huyghe, Nicolas[UCL] Carrasco, Javier De Cuyper, Astrid[UCL] Sinapi, Isabelle Verstraelen, Eléonore[UCL] Goffette, Pierre[UCL] Ghaye, Benoît[UCL] Papier, M. Van Maanen, Aline[UCL] Castella, Marie-Laure[UCL] Galon, Jérôme Van den Eynde, Marc[UCL] (2024) the ESMO Gastrointestinal Cancers Congress 2024 — (Germany) Munich
    • Speech
    Selective internal radiation therapy for neuroendocrine liver metastases: efficacy, safety and prognostic factors. A retrospective single institution study
    Briol, Damien[UCL] Ceratti, Antonino Annet, Laurence[UCL] Dragean, Cristina[UCL] Danse, Etienne[UCL] Trefois, Pierre Lhommel, Renaud[UCL] Goffette, Pierre[UCL] Van den Eynde, Marc[UCL] De Cuyper, Astrid[UCL] Borbath, Ivan[UCL] (2024) 36th Belgian Week of Gastroenterology — (Belgium) Antwerpen
    • Speech
    International real-world study of total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC)
    Audisio, Alexandre Leuven Rectal Cancer Group Vanden Bulcke, Alexander Van den Eynde, Marc[UCL] Dermine, Alexandre Puleo, Francesco[UCL] Diaz, Marie Gilliaux, Quentin[UCL] Deleporte, Amélie Geboes, Karen Martinive, Philippe Vandamme, Timon Hendlisz, Alain van Laethem, Johan Sclafani, Francesco (2024) 36th Belgian Week of Gastroenterology — (Belgium) Antwerpen
    • Journal article
    Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial.
    Raghav, Kanwal Siena, Salvatore Takashima, Atsuo Kato, Takeshi Van den Eynde, Marc[UCL] Pietrantonio, Filippo Komatsu, Yoshito Kawakami, Hisato Peeters, Marc Andre, Thierry Lonardi, Sara Yamaguchi, Kensei Tie, Jeanne Castro, Cristina Gravalos Hsu, Hung-Chih Strickler, John H Kim, Tae-You Cha, Yongjun Barrios, Daniel Yan, Qi Kamio, Takahiro Kobayashi, Kojiro Boran, Aislyn Koga, Makito Allard, John D Yoshino, Takayuki (2024) The Lancet. Oncology — Vol. 25, no.9, p. 1147-1162 (2024)
    • Speech
    600TiP A randomized blinded phase II study of ompenaclid (RGX-202-01) vs placebo in combination with FOLFIRI plus bevacizumab (BEV) in patients (pts) with previously treated RAS mutated (RASmt) advanced/metastatic colorectal cancer (mCRC)
    Elez Fernandez, M.E. Rosello Keranen, S. Paez, D. Jiménez Castro, J. Rivera Herrero, F. Ruiz-Casado, A. Riesco Martinez, M.C. Montagut Viladot, C. Coupez, D. Ducreux, M.P. Loly, C. Martin-Babau, J. Prenen, H. Van den Eynde, Marc[UCL] Borg, C. Cuyle, P-J. de Haar-Holleman, A. Raimbourg, J. Bechar, N. Tabernero, J. (2024) the ESMO Gastrointestinal Cancers Congress 2024 — (Germany) Munich
    • Journal article
    STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancer.
    Saeed, Anwaar Tabernero, Josep Parikh, Aparna Van den Eynde, Marc[UCL] Karthaus, Meinolf Gerlinger, Marco Wang, Zhong Wang, Guan Smith, Robina Hecht, J Randolph (2024) Future oncology — Vol. 20, no.24, p. 1733-1743 (2024)
    • Speech
    LBA2 Interim efficacy analysis of REGINA, a phase II trial of neoadjuvant regorafenib (Rego), nivolumab (Nivo), and short-course radiotherapy (SCRT) in stage II-III rectal cancer (RC)
    Sclafani, F. Bregni, G. Assaf, I. Puleo, F. Vergauwe, P. Prenen, H. Diaz, M. Gokburun, Y. Sanchez, A. Veron Anthoine, G. Moretti, L. Gomez Galdon, M. Liberale, G. Martinive, P. Geboes, K. Carrasco, J. Van den Eynde, Marc[UCL] van Laethem, J-L. Buyse, M.E. Hendlisz, A. (2024) the ESMO Gastrointestinal Cancers Congress 2024 — (Germany) Munich
    • Speech
    159TiP COPERNIC: A study of on-treatment circulating tumour (ct)DNA changes in chemo-refractory colorectal cancer (CRC) patients
    Assaf, Irene Bregni, Giacomo Anthoine, Géraldine Aparicio, Thomas Artru, Pascal Ben Abdelghani, Meher Chibaudel, Benoist Coart, Elisabeth Diaz, Marie Evrard, Camille Geboes, Karen Ghiringhelli, François Puleo, Francesco[UCL] Raimbourg, Judith Vandamme, Timon Van den Eynde, Marc[UCL] Hendlisz, Alain Sclafani, Francesco (2024) the ESMO Gastrointestinal Cancers Congress 2024 — (Germany) Munich
    • Journal article
    Bacteria in metastatic sites: Unveiling hidden players in cancer progression.
    Stevens, Philippe Benidovskaya, Elena Llorens-Rico, Veronica Raes, Jeroen Van den Eynde, Marc[UCL] (2024) Cancer cell — Vol. 42, no.7, p. 1142-1146 (2024)